http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kang, Jeehoon,Han, Jung-Kyu,Ahn, Youngkeun,Chae, Shung Chull,Kim, Young Jo,Chae, In-ho,Hur, Seung-Ho,Seong, In-Whan,Chae, Jei-Keon,Cho, Myeong Chan F K SCHATTAUER VERLAGSGESELLSCHAFT MBH 2018 Thrombosis and Haemostasis Vol.118 No.3
<P>Third-generation P2Y(12) inhibitors (prasugrel, ticagrelor) are recommended in acute myocardial infarction (AMI). We aimed to evaluate the efficacy and safety of third-generation P2Y(12) inhibitors in East Asian AMI patients. From the Korean AMI Registry, 9,355 patients who received dual antiplatelet agent (aspirin with clopidogrel [AC], 6,444 [70.5%] patients; aspirin with prasugrel [AP], 1,100 [11.8%] patients; or aspirin with ticagrelor [AT], 1,811 [19.4%] patients) were analysed. In-hospital endpoints were all-cause mortality or bleeding events during admission and 1-year endpoints were major adverse cardiac and cerebrovascular events(MACCE) andmajor bleedingevents. Regardingin-hospital events, AP andAT showed similar all-causemortality rates but higher bleeding event rates comparedwith AC. This trend was extended to 1-year endpoints; Cox regression analysis showed that thirdgeneration P2Y(12) inhibitors had significantly higher bleeding risk (AP vs. AC: hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.53-2.99; p < 0.001; AT vs. AC: HR, 2.26; 95% CI, 1.73-2.95; p < 0.001). A propensity scorematched tripletof 572 patients showed similar 1year MACCE and higher bleeding events with third-generation P2Y(12) inhibitors (2.1 vs. 2.6 vs. 2.1%, p = 0.790 for MACCE and 3.1 vs. 8.0 vs. 8.0%, p < 0.001 for bleeding events, in AC, AP andAT groups, respectively). Inverse probabilityweighted regression analysis and pooled analysis after randomly imputing missing variables showed consistent results. Collectively, prasugrel and ticagrelor showed similar rates of 1-year MACCE, but a higher rate of bleeding events, compared with clopidogrel in Korean AMI patients. Further studies are warranted to adapt Western guidelines on third-generation P2Y(12) inhibitors for East Asians.</P>
Park, J.W.,Jeon, O.C.,Kim, S.K.,Al-Hilal, T.A.,Lim, K.-M.,Moon, H.T.,Kim, C.Y.,Byun, Y. F K SCHATTAUER VERLAGSGESELLSCHAFT MBH 2011 Thrombosis and haemostasis Vol.105 No.6
<P>This study was designed to develop a solid oral dosage form of deoxycholic acid (DOCA)-conjugated low-molecular-weight heparin (LMWH) and to evaluate its oral absorption, distribution, and metabolic stability for the prospect of providing an orally bioavailable LMWH. The LMWH derivative (LHD) was synthesised and then formulated with solubilisers and other pharmaceutical excipients to form a solid tablet. Its absorption and distribution after oral administration were evaluated in mice, rats, and monkeys. The in vitro metabolic stability of LHD was examined by liver microsome assays. More than 80% of LHD was released from the tablet within 60 minutes, guaranteeing rapid tablet disintegration after oral administration. Oral bioavailability of LHD in mice, rats and monkeys were 16.1 +/- 3.0, 15.6 +/- 6.1, and 15.8 +/- 2.5%, respectively. After the oral administration of (131)I-tyramine-LHD, most of the absorbed drug remained in the blood circulation and was eliminated mainly through the kidneys. LHD was hardly metabolised by the liver microsomes and showed a stable metabolic pattern similar to that of LMWH. In a rat thrombosis model, 10 mg/kg of orally administered LHD reduced thrombus formation by 60.8%, which was comparable to the anti-thrombotic effect of the subcutaneously injected LMWH (100 IU/kg). Solid tablets of LHD exhibited high oral absorption and statistically significant therapeutic effects in preventing venous thromboembolism. Accordingly, LHD tablets are expected to satisfy the unmet medical need for an oral heparin-based anticoagulant as an alternative to injectable heparin and oral warfarin.</P>
Yoon, Minjae,Yang, Pil-Sung,Jang, Eunsun,Yu, Hee Tae,Kim, Tae-Hoon,Uhm, Jae-Sun,Kim, Jong-Youn,Pak, Hui-Nam,Lee, Moon-Hyoung,Lip, Gregory Y. H. F K SCHATTAUER VERLAGSGESELLSCHAFT MBH 2018 Thrombosis and Haemostasis Vol.118 No.7
<P>Conclusion In AF patients, stroke risk as assessed by the CHA(2)DS(2)-VASc score is dynamic and changes over time. Rates of ischaemic stroke increased when patients accumulated risk factors, and were re-classified into higher CHA(2)DS(2)-VASc score categories. Stroke risk assessment is needed at every patient contact, as accumulation of risk factors with increasing CHA(2)DS(2)-VASc score translates to greater stroke risks over time.</P>
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy
Serebruany, V. L.,Kim, M. H.,Cabrera-Fuentes, H. A.,Lee, K.,Cho, Y. R.,Park, K.,Park, T. H.,Kim, Y. D.,Yoon, S.-C. F K SCHATTAUER VERLAGSGESELLSCHAFT MBH 2017 Thrombosis and haemostasis Vol.117 No.5
<P>The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear. We compared cancer and all-cause mortality after dual antiplatelet therapy (DAPT) for the combination of clopidogrel and aspirin (ASA) versus ASA alone over 18 months follow-up in event-free patients at 12 months DAPT from the Health Insurance Review and Assessment (HIRA) dataset via the Korean Outcomes Registry Evaluating Antithrombotics (KOREA). We selected PCI patients who were event free for 12 months and maintained a consistent antiplatelet regimen for 18 more months. The primary endpoints were any cancer and all-cause mortality at 30 months follow-up after PCI. From 320,351 screened post-PCI patient HIRA records, we excluded 294,413 and qualified 25,938, constituting DAPT (n=10,992) and ASA (n=14,946) groups. The Propensity Score Matching (PSM), and Inverse Probability of Treatment Weighting (IPTW) revealed no significant differences in back-ground demographics and clinical characteristics for DAPT versus ASA patients. At 30-months post-PCI, after massive (>91 %) exclusions, cancer risk was higher for continuous DAPT [455 (4.15 %) vs 606 (4.04 %); HR=1.221; 95 % CI: 1.061-1.405; p=0.005], which remained significant by PSM (p=0.006) or IPTW (p=0.007), while all-cause mortality was similar [136 (1.24 %) vs 192 (1.28 %) HR=0.999; 95 % CI: 0.736-1.135; p=0.993]. This analysis suggests a potential mild excess cancer risk, but no mortality benefit in Korean post-PCI patients treated with DAPT for an additional 18 months beyond conventional 12 months DAPT. These data are not supporting continuing DAPT for more than one year in East Asians. Analysing cancer types and assessing potential cancer association with bleeding are warranted.</P>